Terms: = Prostate cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802
318 results:
1. [LncRNA RPL22P1-201 affects prostate cancer cell proliferation, cell cycle, and sensitivity to docetaxel by regulating miR-216b-5p expression].
Yang C; Xue JG
Zhonghua Nan Ke Xue; 2023 Oct; 29(10):881-887. PubMed ID: 38639656
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of Proliferation and Induction of Apoptosis in Prostatic Carcinoma DU145 Cells by Polysaccharides from Yunnan
Yang Z; Chen G
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611854
[TBL] [Abstract] [Full Text] [Related]
3. MYC induces cdk4/6 inhibitors resistance by promoting pRB1 degradation.
Ma J; Li L; Ma B; Liu T; Wang Z; Ye Q; Peng Y; Wang B; Chen Y; Xu S; Wang K; Dang F; Wang X; Zeng Z; Jian Y; Ren Z; Fan Y; Li X; Liu J; Gao Y; Wei W; Li L
Nat Commun; 2024 Feb; 15(1):1871. PubMed ID: 38424044
[TBL] [Abstract] [Full Text] [Related]
4. Curcumin Enhances the Anti-cancer Efficacy of cdk4/6 Inhibitors in prostate cancer.
Zhao H; Ding R; Han J
Arch Esp Urol; 2024 Jan; 77(1):57-66. PubMed ID: 38374014
[TBL] [Abstract] [Full Text] [Related]
5. ER-positive and BRCA2-mutated breast cancer: a literature review.
Li PC; Zhu YF; Cao WM; Li B
Eur J Med Res; 2024 Jan; 29(1):30. PubMed ID: 38184581
[TBL] [Abstract] [Full Text] [Related]
6. [Metastatic castration-resistant prostate cancer-emerging trends in therapy].
von Amsberg G; Todenhöfer T
Urologie; 2023 Dec; 62(12):1289-1294. PubMed ID: 37955661
[TBL] [Abstract] [Full Text] [Related]
7. Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of cdk4/6 Inhibitors in prostate cancer.
Liang H; Yang C; Zeng R; Song Y; Wang J; Xiong W; Yan B; Jin X
Adv Sci (Weinh); 2023 Dec; 10(36):e2302368. PubMed ID: 37949681
[TBL] [Abstract] [Full Text] [Related]
8. Cannabidiol Inhibits the Proliferation and Invasiveness of prostate cancer Cells.
O'Reilly E; Khalifa K; Cosgrave J; Azam H; Prencipe M; Simpson JC; Gallagher WM; Perry AS
J Nat Prod; 2023 Sep; 86(9):2151-2161. PubMed ID: 37703852
[TBL] [Abstract] [Full Text] [Related]
9. Targeted inhibition of mTOR by BML-275 induces mitochondrial-mediated apoptosis and autophagy in prostate cancer.
Li W; Li D; Ma Q; Chen Y; Hu Z; Bai Y; Xie L
Eur J Pharmacol; 2023 Oct; 957():176035. PubMed ID: 37657741
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of Ribonucleotide Reductase Induces Endoplasmic Reticulum Stress and Apoptosis, Leading to the Death of Docetaxel-resistant prostate cancer Cells.
Serttas R; Erdogan S
Anticancer Agents Med Chem; 2023; 23(17):1958-1965. PubMed ID: 37565554
[TBL] [Abstract] [Full Text] [Related]
11. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC; Howell S; Lord SR; Kenny L; Mansi J; Mitri Z; Palmieri C; Chap LI; Richards P; Gradishar W; Sardesai S; Melear J; O'Shaughnessy J; Ward P; Chalasani P; Arkenau T; Baird RD; Jeselsohn R; Ali S; Clack G; Bahl A; McIntosh S; Krebs MG
Nat Commun; 2023 Jul; 14(1):4444. PubMed ID: 37488191
[TBL] [Abstract] [Full Text] [Related]
12. Long-term survival outcomes of salvage [
Ballal S; Yadav MP; Satapathy S; Raju S; Tripathi M; Damle NA; Sahoo RK; Bal C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3777-3789. PubMed ID: 37462775
[TBL] [Abstract] [Full Text] [Related]
13. Veratramine Inhibits the Cell Cycle Progression, Migration, and Invasion via ATM/ATR Pathway in Androgen-Independent prostate cancer.
Kim HY; Lee SW; Choi SK; Ashim J; Kim W; Beak SM; Park JK; Han JE; Cho GJ; Ryoo ZY; Jeong J; Lee YH; Jeong H; Yu W; Park S
Am J Chin Med; 2023; 51(5):1309-1333. PubMed ID: 37385965
[TBL] [Abstract] [Full Text] [Related]
14. Pyrogallol from
Arjsri P; Mapoung S; Semmarath W; Srisawad K; Tuntiwechapikul W; Yodkeeree S; Dejkriengkraikul P
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047425
[TBL] [Abstract] [Full Text] [Related]
15. The ethanol extract of Cyperus exaltatus var. iwasakii exhibits cell cycle dysregulation, ERK1/2/p38 MAPK/AKT phosphorylation, and reduced MMP-9-mediated metastatic capacity in prostate cancer models in vitro and in vivo.
Kim H; Hwang B; Cho S; Kim WJ; Myung SC; Choi YH; Kim WJ; Lee S; Moon SK
Phytomedicine; 2023 Jun; 114():154794. PubMed ID: 37011419
[TBL] [Abstract] [Full Text] [Related]
16. Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges.
Papavasileiou G; Tsilingiris D; Spyrou N; Vallianou NG; Karampela I; Magkos F; Dalamaga M
Semin Cancer Biol; 2023 Jun; 91():70-98. PubMed ID: 36893965
[TBL] [Abstract] [Full Text] [Related]
17. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
[TBL] [Abstract] [Full Text] [Related]
18. SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of cdk4/6 Inhibitors.
Huang Z; Li X; Tang B; Li H; Zhang J; Sun R; Ma J; Pan Y; Yan B; Zhou Y; Ding D; Yan Y; Jimenez R; Orme JJ; Jin X; Yang J; Huang H; Jia Z
Cancer Res; 2023 Mar; 83(6):875-889. PubMed ID: 36637424
[TBL] [Abstract] [Full Text] [Related]
19. Decursin inhibits EGFR-ERK1/2 signaling axis in advanced human prostate carcinoma cells.
Bhat TA; Dheeraj A; Nambiar DK; Singh SP; Yim DS; Singh RP
Prostate; 2023 May; 83(6):534-546. PubMed ID: 36597263
[TBL] [Abstract] [Full Text] [Related]
20. Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer.
Franks J; Caston NE; Elkhanany A; Gerke T; Azuero A; Rocque GB
Breast Cancer Res Treat; 2023 Feb; 197(3):673-681. PubMed ID: 36539670
[TBL] [Abstract] [Full Text] [Related]
[Next]
